Invega Shortage: What Providers and Prescribers Need to Know in 2026

While paliperidone (Invega) oral extended-release tablets are not on an active FDA shortage list as of 2026, many prescribers are hearing from patients who are having difficulty filling their prescriptions. This article is designed for psychiatrists, PCPs, NPs, and other clinicians managing patients on paliperidone — covering the clinical landscape, bridging options, patient communication strategies, and cost management resources.

Understanding the Current Availability Landscape

Paliperidone availability in 2026 varies significantly by formulation:

Oral paliperidone ER (generic Invega): Generally available from multiple generic manufacturers. Patients reporting trouble filling this form are most commonly encountering insurance/formulary barriers, rather than true supply shortages. Generic is the most accessible and cost-effective form.

Brand-name Invega oral tablets: Less commonly stocked because generic substitution is standard practice. DAW (dispense as written) patients may encounter real stocking issues.

Invega Sustenna (PP1M) / Trinza (PP3M) / Hafyera (PP6M): Brand-only specialty injectables. Distribution is through specialty pharmacies and in-office stock. Prior authorization is almost universal. Access timelines can be 2–4 weeks from prescription to first injection, creating clinical gaps, particularly for newly prescribed patients.

Clinical Considerations When Patients Can't Access Paliperidone

Abrupt discontinuation of paliperidone carries significant risk of psychotic relapse. As prescribers, the clinical priority is maintaining medication coverage while supply or authorization issues are resolved. Consider the following:

Bridging Strategy 1: Oral Paliperidone ER (for LAI patients)

For patients on Invega Sustenna who face a delay in receiving their next injection, bridging with oral paliperidone ER is the most straightforward approach. The same active compound maintains drug levels. Typical oral dosing for adults: 6 mg once daily (range 3–12 mg). Monitor for symptom changes during the bridging period.

Bridging Strategy 2: Risperidone

Because paliperidone is the active metabolite of risperidone (9-hydroxyrisperidone), transitioning between the two is pharmacologically simpler than most antipsychotic switches. Dosing equivalence is not perfectly established, but approximate conversions include:

Paliperidone 3 mg ≈ Risperidone 1–2 mg

Paliperidone 6 mg ≈ Risperidone 2–4 mg

Paliperidone 12 mg ≈ Risperidone 4–6 mg

Clinical note: CYP2D6 status affects risperidone metabolism but not paliperidone (which is primarily renally cleared). In poor CYP2D6 metabolizers or patients with hepatic impairment, paliperidone may be preferable; however, during a temporary bridge, risperidone is usually well-tolerated.

Other Formulary Alternatives to Consider

For patients requiring a more permanent alternative due to ongoing access or cost issues, the following atypical antipsychotics are FDA-approved for schizophrenia:

Aripiprazole (Abilify / generic): Partial D2 agonist; less prolactin elevation and lower metabolic burden; available as monthly LAI (Abilify Maintena). Good alternative for patients concerned about hormonal side effects.

Quetiapine (Seroquel / generic): Low EPS; sedating; widely available; good for patients with comorbid sleep disturbance. No LAI formulation available.

Olanzapine (Zyprexa / generic): Highly effective for positive and negative symptoms; significant metabolic risk (weight gain, dysglycemia); also available as LAI (Zyprexa Relprevv, requires REMS program).

Lurasidone (Latuda / generic): Favorable metabolic profile; requires ≥350 calorie meal for adequate absorption; once daily.

Navigating Prior Authorization for Invega Sustenna / Trinza / Hafyera

Prior authorization for the Invega LAI family is nearly universal across commercial, Medicare, and Medicaid plans. Key documentation requirements typically include:

Confirmed diagnosis of schizophrenia or schizoaffective disorder (ICD-10 F20.x or F25.x)

Documentation of trial of oral antipsychotic(s) — for Sustenna, evidence of tolerability to oral paliperidone or risperidone is usually required

Clinical justification for LAI (e.g., adherence challenges, prior relapse due to oral medication non-compliance, patient or caregiver preference)

For Trinza and Hafyera: documentation of adequate stabilization period on the preceding formulation (Sustenna for Trinza; Sustenna or Trinza for Hafyera)

Submit PAs early and proactively document adherence rationale in chart notes. Janssen's reimbursement support team (1-877-227-3728) can assist with PA submission and appeals.

Patient Communication: What to Tell Your Patients

Patients dealing with medication access issues need reassurance and a concrete plan. Key talking points:

Do not stop taking paliperidone abruptly — contact the office before running out.

Generic paliperidone ER is the same drug and much cheaper — most patients on oral tablets can switch without clinical concern.

Encourage patients to use tools like medfinder to locate pharmacies with stock rather than giving up after one or two calls.

For injection patients: provide a written bridge plan so patients and family know exactly what to do if an injection is delayed.

Resources for Providers

Janssen CarePath: 1-877-227-3728 or myjanssencarepath.com — PA support, specialty pharmacy coordination, patient savings programs

FDA Drug Shortage Database: fda.gov/drugs/drug-safety-and-availability/drug-shortages — real-time shortage listings

ASHP Drug Shortage Resource Center: ashp.org — shortage guidance and therapeutic substitution protocols

medfinder for Providers:

medfinder's provider platform helps clinical teams find pharmacies that carry specific medications for patients, reducing the burden on your staff and helping patients stay on therapy.